Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Cocrystal Pharma, Inc. Common Stock

COCP

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.945 – $1.02
Volume 33,435
Market cap $19M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$18.88M
Price / earnings
—
Price / book
18.08×
Price / sales
57.21×
EV / sales
50.63×
EV / EBITDA
-1.66×

Profitability

Earnings per share
-$0.52
Return on assets
-213.77%
Return on equity
-951.92%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.24×
Quick ratio
1.24×
Cash ratio
0.83×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.97M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for COCP, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$105K$225K$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$105K$225K$0$0$0$0$0$0
Selling, general and administrative$1.15M$1.21M$862K$1.14M$986K$981K$1.19M$1.8M
Research and development$2.14M$1.37M$1.62M$954K$1.12M$1.36M$2.04M$3.24M
Total operating expenses$3.29M$2.58M$2.48M$2.09M$2.11M$2.34M$3.23M$5.04M
Operating income-$3.18M-$2.36M-$2.48M-$2.09M-$2.11M-$2.34M-$3.23M-$5.04M
Interest expense$10K$22K$47K$22K$28K$37K$55K$111K
Income before taxes-$3.16M-$2.3M-$2.43M-$2.05M-$2.06M-$2.3M-$3.27M-$4.94M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.16M-$2.3M-$2.43M-$2.05M-$2.06M-$2.3M-$3.27M-$4.94M
Net income attributable to common shareholders-$3.16M-$2.3M-$2.43M-$2.05M-$2.06M-$2.3M-$3.27M-$4.94M
EBITDA-$3.17M-$2.34M-$2.47M-$2.08M-$2.09M-$2.32M-$3.2M-$5.01M
Basic earnings per share-$0.23-$0.17-$0.18-$0.19-$0.20-$0.23-$0.32-$0.49
Diluted earnings per share-$0.23-$0.17-$0.18-$0.19-$0.20-$0.23-$0.32-$0.49

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

Cocrystal Pharma announced completion of dosing in its Phase 1b challenge study for CDI-988, an oral antiviral candidate for norovirus prevention and treatment, with no serious adverse events reported. The company received a $5 million private placement investment from OPKO Health and appointed antiviral development expert Carol Brosgart, MD to its Board. Preliminary efficacy results are expected near the end of 2026.

GlobeNewswire Inc.

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Cocrystal Pharma completed enrollment in the first cohort of a Phase 1b challenge study for CDI-988, an oral protease inhibitor for norovirus prevention and treatment. The company received FDA Fast Track designation for CDI-988 and an initial $225,000 NIH SBIR grant for influenza A/B antiviral development. Q1 2026 revenue was $225,000 from grant income, with net loss of $2.3 million and cash position of $4.7 million.

GlobeNewswire Inc.

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Cocrystal Pharma announced that its oral norovirus protease inhibitor CDI-988 will be presented at the ICAR 2026 conference in Prague. The company will present Phase 1 data and updates from an ongoing Phase 1b challenge study at Emory University School of Medicine. CDI-988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections, with no approved antiviral therapies or vaccines currently available for this indication.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 11, 20221-for-12reverse split
Jan 24, 20181-for-30reverse split
Mar 15, 201110-for-1forward split